Efficacy of gabapentin in the management of chemotherapy‐induced peripheral neuropathy

Ravi D. Rao(Mayo Clinic), Paul J. Novotny(Alliance for Clinical Trials in Oncology), Gamini S. Soori(Missouri Valley Cancer Consortium), Leila A. Kutteh(Cedar Rapids Public Library), David O. Warner(Mayo Clinic in Arizona), Jeff A. Sloan(Mayo Clinic in Florida), Daniel A. Nikcevich(Duluth Clinic), Gilbert Y. Wong(Mayo Clinic), Charles L. Loprinzi(Mayo Clinic in Arizona), John C. Michalak(Hematology Oncology Associates)
Cancer
September 12, 2007
10.1002/cncr.23008
Cited by 355

Related Papers

Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
Patient engagement in research: a systematic review
|BMC Health Services Research|2014|1.8k
Early Exposure to Anesthesia and Learning Disabilities in a Population-based Birth Cohort
|Anesthesiology|2009|1.4k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2014|1.2k
Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
|JAMA Oncology|2015|1k